Gastroenterology
Volume 137, Issue 3 , Pages 885-891.e1 , September 2009

Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo

Received 15 March 2009 ,Accepted 28 May 2009.

References 

  1. Amodio P, Del Piccolo F, Petteno E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35:37–45
  2. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96:2718–2723
  3. Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology. 1999;30:612–622
  4. Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28:1215–1225
  5. Groeneweg M, Moerland W, Quero JC, et al. Screening of subclinical hepatic encephalopathy. J Hepatol. 2000;32:748–753
  6. Saxena N, Bhatia M, Joshi YK, et al. Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol. 2001;16:322–327
  7. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001;16:37–41
  8. Sharma P, Sharma BC, Puri V, et al. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007;47:67–73
  9. Romer Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45:879–885
  10. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30:890–895
  11. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Treatment of hepatic encephalopathy (New perspectives on old ideas). In:  Butterworth RF,  Pomier-Layrargues G editor. Hepatic encephalopathy (Pathophysiology and treatment). Clifton, NJ: Humana; 1987;p. 469–481
  12. Blei AT, Córdoba Jfor the Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976
  13. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473–479
  14. Bouhnik Y, Attar A, Joly FA, et al. Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur J Clin Nutr. 2004;58:462–466
  15. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. Gastroenterology. 1977;72:573–583
  16. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy (A controlled, double-blind clinical trial). Am J Dig Dis. 1978;23:398–406
  17. Camma C, Fiorello F, Tine F, et al. Lactitol in treatment of chronic hepatic encephalopathy (A meta-analysis). Dig Dis Sci. 1993;38:916–922
  18. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046–1051
  19. Kircheis G, Nilius R, Berndt H, et al. Therapeutic efficacy of 1-ornithine-l-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: a placebo-controlled double-blind study. Hepatology. 1997;25:1351–1360
  20. Stauch S, Kircheis G, Adler G, et al. 1-ornithine-l-aspartate granulate in the treatment of latent and mild chronic hepatic encephalopathy (HE): a placebo controlled double-blind study. J Hepatol. 1998;28:856–864
  21. Morgan MH, Read AE, Speller DCE. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982;23:1–7
  22. Hawkins RA, Jessy J, Mans AM, et al. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol. 1994;368:125–134
  23. Miglio F, Valpiani D, Rossellini SR, et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy (A double-blind, randomized trial). Curr Med Res Opin. 1997;13:593–601
  24. Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci. 2000;45:1549–1552
  25. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997;26:1410–1414
  26. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549–559
  27. Sharma P, Sharma BC, Puri V, et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2008;20:506–511
  28. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–721
  29. Dhiman RK, Saraswat VA, Verma M, et al. Figure connection tests: a universal test for assessment of mental state. J Gastroenterol Hepatol. 1995;10:14–23
  30. Ramalingaswamy P. Manual of Indian Adaptation of WAIS Performance Scale. Delhi: Manasayan. 1974;2–:29
  31. Riggio O, Balducci G, Ariosto F, et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig Dis Sci. 1989;34:823–829
  32. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl 1):3–9
  33. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology. 1987;7:1278–1284
  34. Heredia D, Caballería J, Arroyo V, et al. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE) (A controlled trial). J Hepatol. 1987;4:293–298
  35. Heredia D, Terés J, Orteu N, et al. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. J Hepatol. 1988;7:106–110
  36. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy (A double-blind, randomised, cross-over study). J Hepatol. 1987;4:236–244
  37. Lanthier PL, Morgan MY. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut. 1985;26:415–420
  38. Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16:531–535
  39. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000;95:2029–2034
  40. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353–358
  41. Deschenes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol. 1999;94:2193–2197
  42. Campillo B, Pernet P, Bories PN, et al. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol. 1999;11:755–759
  43. Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003;50:1482–1486
  44. Munoz SJ. Hepatic encephalopathy. Med Clin North Am. 2008;92:795–812
  45. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora. Drugs. 1997;53:930–942
  46. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441–1449

 Conflicts of interest The authors disclose no conflicts.

PII: S0016-5085(09)00904-4

doi: 10.1053/j.gastro.2009.05.056

Gastroenterology
Volume 137, Issue 3 , Pages 885-891.e1 , September 2009

Article Tools

* Image Usage & Resolution